EQS-Adhoc

Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals

EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals 15-March-2021 / 06:46 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Longboard Pharmaceuticals (Nasdaq: LBPH), a private company in the portfolio of HBM Healthcare Investments, completed its IPO last Friday. The company raised USD 80 million in new capital by issuing 5 million shares at a price of USD 16.00 each. On the first day of trading, the share price closed at USD 16.65 (+4.1%).

HBM Healthcare Investments invested USD 10 million in Longboard Pharmaceuticals in October 2020 and increased its stake by a further USD 8 million in the IPO. Following the IPO, HBM Healthcare Investments holds 1.88 million shares with a total value of USD 31.3 million. 

Longboard Pharmaceuticals focuses on the development of novel, transformative drugs for neurological diseases. The most advanced compound, LP352, an oral, centrally acting 5-HT2c superagonist, is being tested for the potential treatment of developmental and epileptic encephalopathies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic disorders.

---

End of ad hoc announcement

---

Language:	English
Company:	HBM Healthcare Investments AG
	Bundesplatz 1
	6300 Zug
	Switzerland
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	https://www.hbmhealthcare.com
ISIN:	CH0012627250
Valor:	1262725
Listed:	SIX Swiss Exchange
EQS News ID:	1175438

End of Announcement	EQS Group News Service

1175438  15-March-2021 CET/CEST